Hou, Z.; Lin, S.; Du, T.; Wang, M.; Wang, W.; You, S.; Xue, N.; Liu, Y.; Ji, M.; Xu, H.;
et al. Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals 2025, 18, 1355.
https://doi.org/10.3390/ph18091355
AMA Style
Hou Z, Lin S, Du T, Wang M, Wang W, You S, Xue N, Liu Y, Ji M, Xu H,
et al. Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals. 2025; 18(9):1355.
https://doi.org/10.3390/ph18091355
Chicago/Turabian Style
Hou, Zhenyan, Songwen Lin, Tingting Du, Mingjin Wang, Weida Wang, Shen You, Nina Xue, Yichen Liu, Ming Ji, Heng Xu,
and et al. 2025. "Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749" Pharmaceuticals 18, no. 9: 1355.
https://doi.org/10.3390/ph18091355
APA Style
Hou, Z., Lin, S., Du, T., Wang, M., Wang, W., You, S., Xue, N., Liu, Y., Ji, M., Xu, H., & Chen, X.
(2025). Correction: Hou et al. S-72, a Novel Orally Available Tubulin Inhibitor, Overcomes Paclitaxel Resistance via Inactivation of the STING Pathway in Breast Cancer. Pharmaceuticals 2023, 16, 749. Pharmaceuticals, 18(9), 1355.
https://doi.org/10.3390/ph18091355
